Adicet Bio (ACET) Total Liabilities (2017 - 2026)

Adicet Bio's Total Liabilities history runs 10 years deep, the most recent figure standing at $29.3 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 1.7% year-over-year to $29.3 million; the TTM figure through Mar 2026 stood at $29.3 million (down 1.7% YoY), while the FY2025 annual figure was $33.1 million, down 1.38% from the prior year.
• Total Liabilities for Q1 2026 stood at $29.3 million, down from $33.1 million in the prior quarter.
• The five-year high for Total Liabilities was $38.8 million in Q1 2023, with the low at $29.3 million in Q1 2026.
• The 5-year median for Total Liabilities is $34.3 million (2024), against an average of $34.3 million.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities plunged 35.9% in 2022, then soared 31.98% in 2023.
• Adicet Bio's Total Liabilities stood at $38.4 million in 2022, then dropped by 3.21% to $37.1 million in 2023, then retreated by 9.46% to $33.6 million in 2024, then slipped by 1.38% to $33.1 million in 2025, then decreased by 11.55% to $29.3 million in 2026.
• Business Quant data shows ACET's Total Liabilities at $29.3 million in Q1 2026, $33.1 million in Q4 2025, and $31.3 million in Q3 2025.